Anthem Blue Cross Blue Shield of Georgia prior authorization, page 18

CPT code lookup

Each row is one code from the public prior authorization list. The description is the procedure or service name on that source row. This is not a coverage decision.

Prior authorization codes

Prior authorization codes
CodeDescriptionSource
81250G6PC (glucose-6-phosphatase, catalytic subunit) (eg, Glycogen storage disease, type 1a, von Gierke disease) gene analysis, common variants (eg, R83C, Q347X)Standard Local Prior Authorization Code List, Pg 43 Original policy
81251GBA (glucosidase, beta, acid) (eg, Gaucher disease) gene analysis, common variants (eg, N370S, 84GG, L444P, IVS2+1G>A)Standard Local Prior Authorization Code List, Pg 43 Original policy
81252GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; full gene sequenceStandard Local Prior Authorization Code List, Pg 43 Original policy
81253GJB2 (gap junction protein, beta 2, 26kDa; connexin 26) (eg, nonsyndromic hearing loss) gene analysis; known familial variantsStandard Local Prior Authorization Code List, Pg 43 Original policy
81254GJB6 (gap junction protein, beta 6, 30kDa, connexin 30) (eg, nonsyndromic hearing loss) gene analysis, common variants (eg, 309kb [del(GJB6- D13S1830)] and 232kb [del(GJB6-D13S1854)])Standard Local Prior Authorization Code List, Pg 43 Original policy
81255HEXA (hexosaminidase A [alpha polypeptide]) (eg, Tay-Sachs disease) gene analysis, common variants (eg, 1278insTATC, 1421+1G>C, G269S)Standard Local Prior Authorization Code List, Pg 43 Original policy
81256HFE (hemochromatosis) (eg, hereditary hemochromatosis) gene analysis, common variants (eg, C282Y, H63D)Standard Local Prior Authorization Code List, Pg 43 Original policy
81257HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; common deletions or variant (eg, Southeast Asian, Thai, Filipino, Mediterranean, alpha3.7, alpha4.2, alpha20.5, Constant Spring)Standard Local Prior Authorization Code List, Pg 43 Original policy
81258HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; known familial variantStandard Local Prior Authorization Code List, Pg 43 Original policy
81259HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; full gene sequenceStandard Local Prior Authorization Code List, Pg 43 Original policy
81260IKBKAP (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase, Complex-associated protein) (eg, familial dysautonomia) gene analysis, common variants (eg, 2507+6T>C, R696P)Standard Local Prior Authorization Code List, Pg 43 Original policy
81261IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); amplified methodology (eg, polymerase chain reaction)Standard Local Prior Authorization Code List, Pg 44 Original policy
81262IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (eg, Southern blot)Standard Local Prior Authorization Code List, Pg 44 Original policy
81263IGH@ (Immunoglobulin heavy chain locus) (eg, leukemia and lymphoma, B-cell), variable region somatic mutation analysisStandard Local Prior Authorization Code List, Pg 44 Original policy
81264IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)Standard Local Prior Authorization Code List, Pg 44 Original policy
81265Comparative analysis using Short Tandem Repeat (STR) markers; patient and comparative specimen (eg, pre-transplant recipient and donor germline testing, post-transplant non-hematopoietic recipient germline [eg, buccal swab or other germline tissue sample] and donor testing, twin zygosity testing, or maternal cell contamination of fetal cells)Standard Local Prior Authorization Code List, Pg 44 Original policy
81266Comparative Analysis Using Short Tandem Repeat (Str) Markers; Each Additional Specimen (Eg, Additional Cord Blood Donor, Additional Fetal Samples From Different Cultures, Or AStandard Local Prior Authorization Code List, Pg 44 Original policy
81269HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; duplication/deletion variantsStandard Local Prior Authorization Code List, Pg 44 Original policy
81270JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.Val617Phe (V617F) variantStandard Local Prior Authorization Code List, Pg 44 Original policy
81271HTT (huntingtin) (eg, Huntington disease) gene analysis; evaluation to detect abnormal (eg, expanded) allelesStandard Local Prior Authorization Code List, Pg 44 Original policy
81272KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, gastrointestinal stromal tumor [GIST], acute myeloid leukemia, melanoma), gene analysis, targeted sequence analysis (eg, exons 8, 11, 13, 17, 18)Standard Local Prior Authorization Code List, Pg 44 Original policy
81273KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, mastocytosis), gene analysis, D816 variant(s)Standard Local Prior Authorization Code List, Pg 44 Original policy
81274HTT (huntingtin) (eg, Huntington disease) gene analysis; characterization of alleles (eg, expanded size)Standard Local Prior Authorization Code List, Pg 44 Original policy
81275Kras (V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene) (Eg, Carcinoma) Gene Analysis, Variants In, Codons 12 And 13Standard Local Prior Authorization Code List, Pg 44 Original policy
81276KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; additional variant(s) (eg, codon 61, codon 146)Standard Local Prior Authorization Code List, Pg 44 Original policy
81277Cytogenomic neoplasia (genome-wide) microarray analysis, interrogation of genomic regions for copy number and loss-of-heterozygosity variants for chromosomal abnormalitiesStandard Local Prior Authorization Code List, Pg 44 Original policy
81278IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitativeStandard Local Prior Authorization Code List, Pg 44 Original policy
81279JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13)Standard Local Prior Authorization Code List, Pg 44 Original policy
81283IFNL3 (interferon, lambda 3) (eg, drug response), gene analysis, rs12979860 variantStandard Local Prior Authorization Code List, Pg 44 Original policy
81284FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) allelesStandard Local Prior Authorization Code List, Pg 44 Original policy
81285FXN (frataxin) (eg, Friedreich ataxia) gene analysis; characterization of alleles (eg, expanded size)Standard Local Prior Authorization Code List, Pg 44 Original policy
81286FXN (frataxin) (eg, Friedreich ataxia) gene analysis; full gene sequenceStandard Local Prior Authorization Code List, Pg 44 Original policy
81287MGMT (O-6-methylguanine-DNA methyltransferase) (eg, glioblastoma multiforme) promoter methylation analysisStandard Local Prior Authorization Code List, Pg 44 Original policy
81288MLH1 (mutL homolog 1, colon, Cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; promoter methylation analysisStandard Local Prior Authorization Code List, Pg 45 Original policy
81289FXN (frataxin) (eg, Friedreich ataxia) gene analysis; known familial variant(s)Standard Local Prior Authorization Code List, Pg 45 Original policy
81290MCOLN1 (mucolipin 1) (eg, Mucolipidosis, type IV) gene analysis, common variants (eg, IVS3-2A>G, del6.4kb)Standard Local Prior Authorization Code List, Pg 45 Original policy
81291MTHFR (5,10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoagulability) gene analysis, common variants (eg, 677T, 1298C)Standard Local Prior Authorization Code List, Pg 45 Original policy
81292MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysisStandard Local Prior Authorization Code List, Pg 45 Original policy
81293MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variantsStandard Local Prior Authorization Code List, Pg 45 Original policy
81294MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variantsStandard Local Prior Authorization Code List, Pg 45 Original policy
81295MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysisStandard Local Prior Authorization Code List, Pg 45 Original policy
81296MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variantsStandard Local Prior Authorization Code List, Pg 45 Original policy
81297MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variantsStandard Local Prior Authorization Code List, Pg 45 Original policy
81298MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysisStandard Local Prior Authorization Code List, Pg 45 Original policy
81299MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variantsStandard Local Prior Authorization Code List, Pg 45 Original policy
81300MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variantsStandard Local Prior Authorization Code List, Pg 45 Original policy
81301Microsatellite instability analysis (eg, hereditary non- polyposis colorectal cancer, Lynch syndrome) of markers for mismatch repair deficiency (eg, BAT25, BAT26), includes comparison of neoplastic and normal tissue, if performedStandard Local Prior Authorization Code List, Pg 45 Original policy
81302MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; full sequence analysisStandard Local Prior Authorization Code List, Pg 45 Original policy
81303MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; known familial variantStandard Local Prior Authorization Code List, Pg 45 Original policy
81304MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; duplication/deletion variantsStandard Local Prior Authorization Code List, Pg 45 Original policy

Sources

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.